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 Georgios  Papatheodorou ,  MD ;  Elissavet  Konstantellou ,  MD ;  Georgios  Hillas ,  MD ;  Spyros  Papiris ,  MD ; 
 Nikolaos  Koulouris ,  MD ,  FCCP ; and  Petros  Bakakos ,  MD  
 BACKGROUND:  Osteopontin (OPN) is a phosphorylated acidic glycoprotein that can function 
as both an extracellular matrix molecule and a cytokine. Published data support that OPN is 
upregulated in surgical lung tissue samples of patients with COPD. Th e aim of this study was 
to determine the levels of OPN in sputum supernatants of patients with COPD and to investi-
gate possible associations with mediators and cells involved in the infl ammatory and remodel-
ing process as well as with the extent of emphysema. 
 METHODS:  Seventy-seven patients with COPD and 40 healthy subjects (20 smokers) were 
studied. All subjects underwent lung function tests, sputum induction for cell count identifi -
cation, and OPN, transforming growth factor- b 1 , matrix metalloproteinase (MMP)-2, IL-8, 
and leukotriene-4 measurement in sputum supernatants. High-resolution CT (HRCT) scan of 
the chest was performed for quantifi cation of emphysema. 
 RESULTS:  OPN levels (pg/mL) were significantly higher in patients with COPD compared 
with healthy smokers and nonsmokers (median [interquartile range], 1,340 [601, 6,227] vs 101 
[77, 110] vs 68 [50, 89], respectively;  P  , .001). Regression analysis showed a signifi cant asso-
ciation between OPN and sputum neutrophils, IL-8, MMP-2, and the extent of emphysema. 
Th e associations previously listed were not observed in healthy subjects. 
 CONCLUSIONS:  OPN levels are higher in patients with COPD compared with healthy subjects. 
OPN may play a role in the neutrophilic infl ammation and in the pathogenesis of emphysema. 
 COPD is a destructive lung disorder characterized by 
infl ammatory and tissue remodeling processes that is 
associated with a chronic enhanced infl ammatory 
response in the airways and the lung to noxious parti-
cles or gases. Pathologic features of COPD are pulmo-
nary infl ammation, remodeling-like changes in mucosal 
lung tissue, fi brosis, and tissue injury. 1 Although consid-
erable information has been gathered concerning the 
role of diff erent agents in the promotion of infl amma-
tion and airway destruction in the acute setting of the 
disease, relatively little is known about signaling path-
ways that drive their progressive and chronic nature. 2 
 Osteopontin (OPN) is a phosphorylated acidic glyco-
protein that can function both as an extracellular matrix 
molecule and as a cytokine. Its origin is not well clari-
fi ed, but epithelial cells, macrophages, T cells, and fi bro-
blasts have been shown to express OPN. Limited data 
are available regarding OPN in COPD. Adenosine 
deaminase-defi cient mice develop alveolar airspace 
enlargement that resembles histologic fi ndings of 
patients with emphysema. 3 OPN has been found to be 
associated with alveolar airspace enlargement, neutro-
philia, and elevations of mediators of airspace enlarge-
ment such as matrix metalloproteinases (MMPs) in 
adenosine deaminase-defi cient mice. 3,4 Given that the 
majority of OPN immunolocalization in human COPD 
lung samples was in alveolar macrophages and that 
OPN expression was associated with the severity of air-
fl ow obstruction, it was suggested that OPN may be a 
major mediator of emphysema. 4 We have reported that 
sputum OPN levels are higher in patients with asthma 
who smoke compared with patients with asthma who 
are nonsmokers and in patients with severe refractory 
asthma compared with less severe forms of the disease. 5,6 
 Th e aim of the present study was to evaluate the levels of 
OPN in sputum supernatants of patients with COPD in 
comparison with healthy smokers and nonsmoking 
subjects. We hypothesized that sputum OPN would be 
elevated in patients with COPD compared with healthy 
control subjects and that it would be associated with 
infl ammatory cells and mediators involved in the ongoing 
airway infl ammation process observed in COPD. We 
also hypothesized that OPN levels would be associated 
with the extent of emphysema. 
 Materials and Methods 
 Subjects 
 Patients with COPD were recruited aft er extensive evaluation from an 
open cohort of patients with COPD who were followed in the outpatient 
clinics of the 1st and 2nd Respiratory Medicine Departments of the Uni-
versity of Athens Medical School. Initially, 94 patients were evaluated. 
The diagnosis of COPD and the severity of airflow obstruction was 
established according to the GOLD (Global Initiative for Chronic 
Obstructive Lung Disease) guidelines.  7  Patients had a history of smok-
ing ( .  20 pack-years) and irreversible airflow limitation (reversibil-
ity  ,  12% and  ,  200 mL in FEV 1 aft er  b 2 -agonist inhalation). Subjects 
with a malignant disease were excluded. All patients were clinically stable, 
with no evidence of acute exacerbation for at least 4 weeks prior to enroll-
ment. Twenty healthy nonsmokers and 20 healthy smokers served as con-
trol subjects. Th e healthy subjects were recruited from the staff  of both 
departments and have also been used as a control group in previous stud-
ies of our group.  5 Th e study was approved by the ethics committees of 
both hospitals (Sotiria Hospital and Attikon Hospital Ethics Committee 
No:517/May 2008), and all subjects provided written informed consent. 
 Study Design 
 On day 1, all subjects underwent medical history and physical examina-
tion by a dedicated respiratory physician, lung function measurements, 
and measurement of BMI, and all patients with COPD underwent high-
resolution CT (HRCT) scan of the chest. On day 2, sputum induction 
was performed. All measurements were performed between 8.00  am  
and 10.00  am . All smokers refrained from smoking for at least 2 h, 
under supervision of one of the study coordinators. HRCT scans were 
performed as part of the medical assessment of patients with COPD. 
Patients with fi ndings suspicious for malignancies or nondefi ned con-
ditions were excluded. 
 Induced Sputum 
 Sputum was induced as previously described, using all necessary modi-
fications for safe measurements according to the underlying 
airflow 
 
obstruction. 8 Sputum was processed using selected plugs as previously 
described. 9 Dithiothreitol was added in a volume equal to four times the 
weight of the sputum specimen, and it was further diluted with phosphate-
buffered saline in a volume equal to the sputum plus dithiothreitol. 
Total cell counts were performed on a hemocytometer using Trypan 
blue stain. Slides were prepared by cytospin (Th ermo Fisher Scientifi c 
Inc ) and were stained with May-Grunwald and Giemsa for diff erential 
cell counts. Cell counting was performed by an observer blind to the clin-
ical characteristics of the subjects. At least 500 infl ammatory cells were 
counted in each sample. A sample was considered adequate when the 
patient was able to expectorate at least 2 mL of sputum and the slides con-
tained  , 10% squamous cells on diff erential cell counting. Th e total cell 
count (expressed as the number of cells  3 10 6 ) and the percentage of spu-
tum infl ammatory cells was used for analysis. Sputum supernatants were 
kept at  2 70°C for further measurement of OPN, transforming growth 
factor (TGF)- b 1 , MMP-2, IL-8, and leukotriene B4 (LTB4) (e-Appendix 1). 
 Lung Function 
 FEV 1 , FVC, FEV 1 /FVC ratio, static volumes (functional residual capac-
ity), and diff using capacity of the lung for carbon monoxide (D lco ) 
corrected for hemoglobin levels were measured using a commercially 
available system (MasterScreen Body; CareFusion Corporation), accord-
ing to the American Th oracic Society guidelines. 10,11 
 Mediator Assays 
 MMP-2 (free) and IL-8 were measured using an enzyme-linked immu-
nosorbent assay (ELISA) kit (R&D Systems, Inc) with detection limits 
of 3.5 pg/mL and 0.047 ng/mL, respectively. LTB4 was measured with 
an ELISA kit (Cayman Chemical Company). TGF- b 1 and human OPN 
were measured by ELISA kits (R&D Systems, Inc) with lower detection 
limits of 50 pg/mL and 6 pg/mL, respectively. All values were expressed 
as pg/mL. Th e intraassay and interassay variability were assessed accord-
ing to the manufacturers’ instructions for all the mediators measured 
and were within acceptable coefficient of variation (%). For OPN, 
the intraassay and interassay variabilities were 4% and 6.5%, respec-
tively. Th e recovery and linearity of the assays aft er appropriate spiking 
experiments produced samples with values within the dynamic range 
of the assay. 
 Quantiﬁ cation of Emphysema in Patients With COPD 
 All patients with COPD were submitted to HRCT scan of the chest 
using a Philips Brilliance 64 (Koninklijke Philips N.V.). Th e degree of 
emphysema was calculated by an experienced radiologist using a visual 
emphysema score as previously described. 12 Th e presence of emphyse-
matous lesions involving  . 15% of the pulmonary parenchyma were 
used for the characterization of the emphysematous COPD phenotype, 
as previously described. 13 
 Statistical Analysis 
 Normally distributed data are presented as mean   SD, and skewed data 
are presented as median (interquartile range). Normality of distribution 
was checked with Kolmogorov-Smirnov test. Statistical comparisons 
between groups were performed with one way analysis of variance for 
normally distributed data and Kruskal-Wallis tests for skewed data, 
accompanied by appropriate post hoc tests for multiple comparisons 
(Bonferroni and Dunnett, respectively). Diff erences in numerical vari-
ables between two groups were evaluated with unpaired  t tests or Mann-
Whitney  U tests for normally distributed and skewed data, respectively, 
whereas comparisons of proportions were performed using  x 2 tests. To 
examine the associations between OPN, sputum cells, mediators (IL-8, 
TGF- b 1 , MMP-2, LTB4), lung function tests, and emphysema score, 
linear regression analysis was performed using OPN as the dependent 
variable, after proper adjustments for age, sex, BMI, smoking habit 
(in pack-years), Charlson comorbidity index score, duration of the dis-
ease, and treatment regimens. Data were interpreted as standardized 
coeffi  cients with 95% CIs.  P values  , .05 (two-sided) were considered 
statistically signifi cant. Statistical analysis was performed using SPSS 
16.0 (IBM) and GraphPad Prism 5 (GraphPad Soft ware, Inc). 
 Results 
 Demographic Characteristics 
 Figure 1 presents the fl owchart of patients with COPD 
included in the study. Seventy-seven patients with COPD 
and 40 healthy subjects (20 smokers) were included in the 
study. Forty-one patients with COPD were receiving 
1,000  m g fl uticasone/d or equivalent. Forty-nine patients 
were receiving long-acting  b 2 -agonists, and 61 were 
receiving tiotropium. Sputum induction was well toler-
ated by all patients. Th e demographic characteristics of 
the study population are summarized in  Table 1 . 
 Inﬂ ammatory Variables in Induced Sputum 
 Patients’ infl ammatory variables are summarized in 
 Table 2 . OPN levels (pg/mL) were signifi cantly higher 
in patients with COPD compared with both smoking 
and nonsmoking healthy subjects (median [interquar-
tile range], 1,340 [601, 6,227] vs 101 [77, 110] vs 68 [50, 
89] pg/mL, respectively;  P  , .001). Moreover, healthy
smokers had signifi cantly higher OPN levels compared
with healthy nonsmokers ( Fig 2 ,  Table 2 ). A signifi cant
diff erence in the levels of sputum OPN was observed
between patients with and without signifi cant emphy-
sema on HRCT scan (4,325 [2,051, 12,236] vs 654 [360,
876] pg/mL;  P  , .001), whereas no diff erence was
observed between patients with and without severe dif-
fusing capacity limitation, as expressed by D lco  , 40% 
predicted (1,654 [432, 4,328] vs 1,320 [628, 7,916] pg/mL; 
 P  5 .97). MMP-2, IL-8, TGF- b 1 , and LTB4 levels were 
signifi cantly higher in patients with COPD compared 
with the other study groups ( Table 2 ). 
 Associations of OPN 
 All the signifi cant associations were observed only in 
patients with COPD. No association was observed in 
the healthy smoking and nonsmoking subjects (data not 
shown ). 
 Infl ammatory Biomarkers:  Regression analysis aft er 
proper adjustments provided signifi cant associations 
between log OPN levels and sputum neutrophils. 
Moreover, signifi cant associations were also provided 
between log OPN levels and IL-8 and MMP-2 ( Table 3 ). 
 Emphysema Score:  Using regression analysis aft er proper 
adjustments a signifi cant association was observed 
between log OPN levels and emphysema score ( Table 3 ). 
 Lung Function:  No signifi cant associations between 
OPN and lung function tests were observed in any of the 
study groups ( Table 3 , for patients with COPD). Stepwise 
regression analysis showed that MMP-2 and emphysema 
score represented the strongest associations with OPN 
( R 2  5 0.59,  P  , .001 and  R 2  5 0.51,  P  5 .001, respectively). 
 Discussion 
 Th e major fi nding of the present study is that OPN levels 
in sputum supernatants are signifi cantly higher in 
patients with COPD compared with both smoking and 
nonsmoking healthy subjects. Sputum OPN levels were 
also positively associated with sputum neutrophils, IL-8, 
MMP-2, and emphysema score in patients with COPD. 
Th is is the fi rst study, to our knowledge, that has evaluated 
the levels of OPN in the sputum of patients with COPD  Figure 1 – Flowchart of patients included in the study . 
and its associations with biomarkers of airway 
infl ammation as well as with the radiologic extent of 
emphysema, therefore, providing implications for the 
possible role of OPN in the pathogenesis of COPD. 
 OPN has been shown to be involved in processes related 
to smoking habit. A previous study has found that the 
expression of OPN was highly induced in macrophages 
from BAL fl uid of smokers and that increased expression 
 TABLE 1  ]  Demographic Characteristics of Study Subjects 
Variables 
COPD 
(n  5 77)
Healthy Smokers 
(n  5 20)
Healthy Nonsmokers 
(n  5 20)  P Value a 
Age 62   10 60   6 52   10 .623
Sex, female (male) 17 (60) 7 (13) 5 (15) .425
Smokers, current (former) 36 (41) 13 (7) 0 .540 b 
Duration of the disease, y 7 (5-11) NA NA NA
Smoking, pack-y 70 (58-90) 64 (55-78) 0 .245 b 
BMI, kg/m 2 28   5 27.5   4 27   4 .620
PB FEV 1 , % pred 56 (45-69) c,d 89 (82-95) 95 (88-99)  , .001
PB FVC, % pred 78   17 c,d 91 3 96   10  , .001
PB FEV 1 /FVC, % 55   11 c,d 86 7 87   6  , .001
D LCO, % pred 60   16 c,d 87 7 95   6  , .001
FRC, % pred 112   21 c,d 89 5 89   12  , .001
Charlson index 5 (2-7) 0 0 …
Treatment regimens NA NA NA
 ICS 41
 LABA 49
 Tiotropium 61
 SABA 10
 Normally distributed data are presented as mean   SD, and skewed data are presented as median (interquartile ranges).  P values indicate signiﬁ cant 
diﬀ erences across the three groups. D LCO  5 diﬀ using capacity of the lung for carbon monoxide; FRC  5 functional residual capacity; ICS  5 inhaled 
corticosteroid; LABA  5 long-acting  b 2 -agonist; NA  5 not applicable; PB  5 postbronchodilation; pred  5 predicted; SABA  5 short-acting  b 2 -agonist . 
 a P , .05 considered statistically signiﬁ cant. 
 b Refers to patients with COPD and healthy smokers. 
 c Statistically signiﬁ cant diﬀ erence compared with healthy smokers. 
 d Statistically signiﬁ cant diﬀ erence compared with healthy nonsmokers. 
 TABLE 2  ]  Infl ammatory Variables of Study Subjects 
Variables
COPD 
(n  5 77)
Healthy Smokers 
(n  5 20)
Healthy Nonsmokers 
(n  5 20)  P Value a 
Cells  3 10 6 /mL 3.4 (1.5-5.3) b,c 0.8 (0.5-1.2) 0.8 (0.6-1.1)  , .001
Eosinophils, % 1 (0-3) 0 (0-0.5) 1 (0-2) .085
Neutrophils, % 62 (53-75) b,c 37 (32-44) c 23 (17-25)  , .001
Macrophages, % 35 (24-44) b,c 61 (55-67) c 72 (58-80)  , .001
Lymphocytes, % 1 (0.5-2) 1 (0-1) 0.25 (0-1) .550
OPN, pg/mL 1,340 (601-6,227) b,c 101 (77-110) c 68 (50-89)  , .001
TGF- b 1 , pg/mL 1,245 (873-1,609) b,c 764 (643-902) 850 (645-1,005)  , .001
IL-8, pg/mL 4,567 (3,411-5,412) b,c 899 (823-1,104) c 432 (314-556)  , .001
MMP-2, pg/mL 435 (298-670) b,c 171 (142-241) c 84 (68-102)  , .001
LTB4, pg/mL 190   34 b,c 107   16 96   22 .003
 Normally distributed data are presented as mean   SD, and skewed data are presented as median (interquartile ranges). P values indicate signiﬁ cant 
diﬀ erences across the three groups. LTB4  5 leukotriene B4; MMP  5 matrix metalloproteinase; OPN  5 osteopontin; TGF  5 transforming growth factor. 
 a P  ,  .05 considered statistically signiﬁ cant. 
 b Statistically signiﬁ cant diﬀ erence compared with healthy smokers. 
 c Statistically signiﬁ cant diﬀ erence compared with healthy nonsmokers. 
 Figure 2 – OPN values in log scale (pg/mL) in sputum supernatant of 
patients with COPD and healthy subjects (smokers and nonsmokers). 
* P values indicate signifi cant diff erences across the three groups. #Statis-
tically signifi cant diff erence compared with healthy smokers; $Statisti-
cally signifi cant diff erence compared with healthy nonsmokers. OPN 5
osteopontin. 
levels correlated with lung function impairment in this 
study group. 14 Moreover, Prasse et al, 15 assessed the 
essential role of OPN in smoking-related interstitial 
lung diseases, showing that BAL cells from patients with 
pulmonary Langerhans cell histiocytosis or desquama-
tive interstitial pneumonitis spontaneously produced 
abundant amounts of OPN. In the same study, BAL 
cells from healthy smokers produced 15-fold less OPN, 
and those from nonsmoking healthy volunteers pro-
duced no OPN, suggesting a possible pathogenic role of 
OPN in both pulmonary Langerhans cell histiocytosis 
and desquamative interstitial pneumonitis. In a previous 
study of our group, sputum OPN was higher in smoking 
compared with nonsmoking subjects with asthma, and 
it was positively associated with sputum neutrophils, 
TGF- b 1 , and IL-8, suggesting a possible role for OPN in 
the neutrophilic infl ammation and the remodelling 
process in patients with asthma who smoke. 5 
 OPN levels have also been associated with alveolar air-
space enlargement, as shown by Schneider et al 4 in a 
model of COPD  Ada  2 / 2  double-knockout mice. In that 
study,  Ada  2 / 2  mice exhibited OPN-dependent neutro-
philia, alveolar airspace enlargement, and increases in 
mediators of airspace enlargement, such as MMP-9 and 
its corresponding tissue inhibitor TIMP-1. Th e authors 
of this study additionally showed that patients with 
COPD had increased OPN expression within distal air-
ways that was associated with clinically relevant airway 
obstruction. 4 Although we did not fi nd any correlation 
between OPN levels and lung function parameters, our 
results are compatible with the previously defi ned fi nd-
ings toward the direction of a possible role of OPN in 
the induction of neutrophilic infl ammation and the 
pathogenesis of emphysema in COPD. 
 Confl icting data exist regarding the interaction between 
OPN and TGF- b 1 , as it has been shown that OPN is a 
TGF- b 1 response gene but also that it may function 
 TABLE 3  ]  Regression Analysis Between OPN, Infl ammatory Cells, Mediators, Lung Function Tests, and 
Emphysema Score in Patients With COPD 
Variables  b Standardized Coeﬃ  cient (95% CI) Adjusted  R 2  P Value a 
Total cells  3 10 6 /mL 0.071 ( 2 190, 559) 0.008 .327
Eosinophils, %  2 0.098 ( 2 784, 182) 0.037 .217
Neutrophils, % 0.182 (0.2, 4.8) 0.185 .038
Macrophages, % 0.087 ( 2 64, 145) 0.021 .440
Lymphocytes, % 0.009 ( 2 466, 583) 0.009 .743
MMP-2, pg/mL 0.654 (13, 27) 0.590  , .001
IL-8, pg/mL 0.297 (0.07, 0.3) 0.089 .028
TGF- b 1 , pg/mL 0.162 ( 2 0.07, 5) 0.038 .060
LTB4, pg/mL  2 0.48 ( 2 37, 19) 0.006 .535
Emphysema score 0.311 (741, 2,610) 0.505 .001
FEV 1 , % pred 0.075 ( 2 90, 369)  2 0.044 .226
FEV 1 /FVC, % pred 0.022 ( 2 38, 57)  2 0.031 .683
FRC, % pred  2 0.032 ( 2 201, 129) 0.004 .661
D LCO, % pred  2 0.114 ( 2 0.06, 4.5)  2 0.090 .059
 Regression analysis was performed after proper adjustments for age, sex, BMI, smoking habit (current or former smokers and pack-y), and treatment 
regimens. See  Table 1 and 2 legends for expansion of abbreviations. 
 a P  ,  .05 considered statistically signiﬁ cant. 
upstream of TGF- b 1 by regulating its activation in lung 
fi brosis. 16,17  Our study failed to reveal an association 
between TGF- b 1 and OPN. On the other hand, it has 
been shown that TGF- b induces the secretion and acti-
vation of the proteolytic enzyme MMP-2, and, conversely, 
TGF- b can also be activated by a number of proteases, 
including MMP-2. 18,19  Moreover, in another study it was 
suggested that TGF- b 1 signaling may prevent emphy-
sema development by inhibiting MMP-mediated elastin 
degradation or by promoting synthesis of elastin. 20 
MMP-2 expression has been found to be elevated in the 
lung parenchyma of patients with COPD compared 
with smoking and nonsmoking healthy subjects, and 
such an upregulation has been related to disease 
severity, implying a possible role of MMP-2 in airway 
remodeling in COPD. 21,22  Additionally, other studies 
have demonstrated increased gelatinolytic activity 
linked to sputum MMP-2 and a negative correlation of 
induced sputum MMP-2 with airway obstruction in 
patients with COPD. 23,24  In accordance with the 
described studies, our results showed higher induced 
sputum MMP-2 levels in patients with COPD compared 
with the other two groups. Moreover, Berman et al 17 
showed that MMP-2 expression may be regulated by 
OPN during lung injury in vivo in a model of murine 
bleomycin-induced lung fi brosis. In accordance with 
these fi ndings, our data suggest a role of OPN through 
MMP-2 in the infl ammatory process in the lungs of 
patients with COPD. However, since the activation of 
MMP-2 is a complex process, a more detailed evalua-
tion including measurement of the levels of tissue inhib-
itor of metalloproteinase-2 might be necessary to extract 
safe conclusions. 
 An interesting fi nding of the present study is the corre-
lation of OPN levels to the extent of emphysema, as 
defi ned by the emphysema score calculated in HRCT 
scans. Th e explanation of such a relation between a 
measurable marker in induced sputum supernatant and 
a score yielded from a radiologic evaluation requires 
caution. However, this association of OPN with emphy-
sema may be mediated through MMP-2, a cytokine we 
also found to be associated with OPN. Moreover, a 
study demonstrated that the gene for OPN was highly 
expressed in the lung antigen-presenting cells of smoke-
exposed mice and was required for the development of 
emphysema in vivo through T(H)17 inflammatory 
responses, thus, providing a possible mechanism for the 
induction of emphysema. 25  However, it has to be 
stressed that the association between OPN and paren-
chymal destruction is rather speculative, although the 
 
fact that it was present in the detailed regression analysis 
after correction for all possible confounders is sup-
portive of this relationship. 
 Th e extremely low OPN levels in both smoking and 
nonsmoking healthy subjects may be attributed to the 
absence and/or inactivation of OPN-producing cells. In 
the present study, OPN was positively associated with 
sputum neutrophils and IL-8. Th e association of OPN 
with sputum neutrophils observed in patients with 
COPD is compatible with neutrophilic airway infl am-
mation as a major factor in the pathogenesis of the 
disease. 26 Moreover, the association of OPN with IL-8, 
which is the major chemoattractant for neutrophils, 
provides an explanation for the traffi  cking of neutro-
phils in the airways and the sputum of patients with 
COPD. In a previous study in an experimental model 
of colitis, defective recruitment of neutrophils was 
observed in OPN-null mice, whereas the addition of 
exogenous OPN was associated with a robust increase in 
peritoneal infi ltration of neutrophils. 27 Accordingly, 
OPN could also be directly associated with neutrophilic 
chemotaxis apart from IL-8. Th ese fi ndings support the 
importance of OPN in the recruitment of neutrophils 
and that OPN is a relevant mediator of neutrophil 
chemotaxis. 
 Th e absence of correlation between OPN and lung func-
tion points toward a lack of association of OPN with 
airway obstruction severity. However, this may be 
attributed to the fact that the number of patients with 
COPD evaluated is rather small to draw safe conclu-
sions about the diff erent disease stages according to 
airway obstruction. Additionally, airfl ow limitation as 
expressed by FEV 1 , is the composite terminal eff ect of 
various pathogenic mechanisms in COPD, including 
infl ammation, remodeling, and fi brosis. Previous 
studies have shown associations between the degree of 
airfl ow obstruction and OPN expression in alveolar 
macrophages of smokers 14 and OPN expression in 
human surgical lung tissue samples from patients with 
COPD. 4 Diff erences in sampling material—induced 
sputum vs BAL and lung biopsies—may account for the 
discrepancy of our fi ndings with the previously dis-
cussed studies. Interestingly, of all the associations with 
lung function parameters, the only one presenting a 
trend toward statistical signifi cance with sputum OPN 
levels was D lco ( P  5 .059). Despite the fact that the 
association between D lco and the extent of emphysema 
is rather weak, this fi nding may further support the asso-
ciation between OPN and the extent of parenchymal 
destruction in patients with COPD. Furthermore, it has 
been reported that any associations between D lco and 
infl ammatory biomarkers in patients with predominant 
emphysema are mainly related to the infl ammatory phe-
notype observed in small airways. 28 
 Th is study presents limitations. First, the cross-sectional 
design does not allow us to provide long-term follow-up 
data of the patients. A prospective cohort study eval-
uating the importance of sputum OPN as a predictive 
biomarker of clinically relevant outcomes (eg, exacer-
bations, hospitalizations, and/or mortality) should 
be specifi cally designed for that purpose. Second, 
the absence of biopsy specimens did not allow us 
to investigate structural changes in the airways of 
patients with COPD and their associations with OPN 
levels. However, the fact that sputum OPN presented 
signifi cant associations with emphysema score and 
particular sputum biomarkers related to infl amma-
tion and remodeling, which remained even aft er 
proper adjustments for confounders, provides impor-
tant evidence about the possible role of OPN in these 
processes. Finally, the results of our cross-sectional 
study cannot rule out the possibility that OPN is not 
causal or pathophysiologically related to COPD but 
rather a surrogate marker of infl ammation, specifi c 
to neither obstructive disease nor neutrophilic 
infl ammation. 
 Conclusions 
 OPN levels are signifi cantly elevated in the induced 
sputum of patients with COPD, compared with smoking 
and nonsmoking healthy control subjects. Th e associa-
tions of OPN with sputum neutrophils, IL-8, MMP-2, 
and emphysema score in patients with COPD suggest a 
possible role for OPN in the induction of neutrophilic 
infl ammation and the pathogenesis of emphysema in 
COPD. Given the possible implication of OPN in the 
regulation of multiple processes that promote the patho-
genesis of COPD, our fi ndings suggest that OPN may 
represent an attractive novel biomarker that may serve 
as a possible therapeutic target. 
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